Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Abstract

Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently been adopted. We performed a multiplatform genomic analysis to characterize, in a nonbiased… (More)
DOI: 10.1158/0008-5472.CAN-10-0192

6 Figures and Tables

Topics

  • Presentations referencing similar topics